Merislon 12 Tablet contains Betahistine 12 mg, a histamine analog primarily used in the management of Ménière’s disease and other vestibular disorders characterized by vertigo, tinnitus, and hearing loss. Betahistine acts as a vasodilator, improving microcirculation in the inner ear, thereby reducing endolymphatic pressure and alleviating symptoms associated with vestibular dysfunction. The tablet is indicated for patients experiencing recurrent vertigo attacks, imbalance, and associated auditory symptoms. Merislon 12 is administered orally, with dosage tailored to individual patient needs, typically ranging from 12 mg to 48 mg daily in divided doses. The medication is generally well-tolerated; however, mild adverse effects such as gastrointestinal discomfort, headache, or allergic reactions may occur. It is contraindicated in patients with pheochromocytoma due to potential hypertensive crises and should be used cautiously in individuals with asthma or peptic ulcers. Betahistine does not impair cognitive or motor functions and is considered safe for long-term use under medical supervision. Regular monitoring and consultation with a healthcare provider are recommended to assess therapeutic efficacy and adjust dosing as necessary. Merislon 12 Tablet offers a targeted approach to managing vestibular symptoms, improving patient quality of life through symptomatic relief and enhanced vestibular compensation.